Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LB1.2
- Development stage
- Preclinical
- Lead developer
- Lixte Biotechnology Holdings
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
LB1.2 (also referred to as LB-1.2 or LB102) is a lipid-soluble, small-molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A) with an IC50 of 0.4 µM. Developed by Lixte Biotechnology, it is a homolog of the clinical candidate LB100. Due to its lipid solubility, LB1.2 is designed to cross the blood-brain barrier more effectively than LB100. It acts as a chemo-sensitizer and radio-sensitizer, enhancing the cytotoxic effects of chemotherapeutic agents such as temozolomide and doxorubicin. In preclinical models, LB1.2 has demonstrated efficacy against glioblastoma multiforme (GBM), neuroblastoma, and pheochromocytoma by preventing DNA damage-induced cell cycle arrest, promoting mitotic catastrophe, and inducing apoptosis.
- Other names
- LB 1.2LB1.2LB-1.2LB 102LB102LB-102
02
Targets
PP2A (Protein phosphatase 2A)
Beyond the preview
Go deeper on LB1.2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LB1.2.